Biotech Values

[DewDiligence]

TMO—Agree re the impropriety excluding restructuring/rebalancing costs from non-GAAP EPS for a “roll-up” company whose continued restructuring is an integral part of the business model.

This doesn’t necessarily mean that I wouldn’t own the stock, but it does mean that I wouldn’t rely on non-GAAP EPS for valuation purposes.